PDSB stock forecast, quote, news & analysis
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more
Why PDS Biotechnology (PDSB) Stock Is Down -26% in the Last 30 Days
Key Takeaways
- PDS Biotechnology shares fell approximately 26% over the last 30 days, declining from $0.8991 on June 29, 2026, to $0.6649 on July 29, 2026.
- Heavy dilution concerns weighed on the stock after the company registered up to 13.32 million shares for resale by selling stockholders and filed a $50 million at-the-market equity offering program.
- A $6 million convertible promissory note with attached warrants, which closed in mid-June, added further overhang from potential future conversion and exercise activity.
- The stock fell back below the $1.00 Nasdaq minimum bid price threshold, reviving delisting risk despite briefly regaining compliance in early June.
- Positive clinical data for PDS01ADC in colorectal and prostate cancers and a promising VERSATILE-003 protocol amendment have so far failed to offset financing-related headwinds.
- Analyst consensus remains a "Strong Buy" with an average price target of $7.50, but near-term capital needs continue to dominate investor sentiment.
PDS Biotechnology (PDSB) Company Overview and Market Position
PDS Biotechnology Corporation is a clinical-stage immunotherapy company headquartered in Princeton, New Jersey, focused on developing targeted cancer treatments using its proprietary Versamune® T-cell activating platform. The company's lead candidate, PDS0101 (Versamune® HPV), is in a pivotal Phase 3 trial for HPV16-positive recurrent and/or metastatic head and neck cancer, in combination with Merck's MRK KEYTRUDA® (pembrolizumab). PDS Biotech is also advancing PDS01ADC, a tumor-targeting IL-12 immunocytokine, in multiple Phase 2 studies for metastatic colorectal cancer and castration-resistant prostate cancer, conducted in collaboration with the National Cancer Institute. With no approved products or revenue, the company remains a pre-commercial biotech that funds operations through equity and debt financing, making capital markets access a critical component of its business model.
PDS Biotechnology (PDSB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PDSB declined from a closing price of $0.8991 on June 29, 2026, to $0.6649 on July 29, 2026, representing a drop of approximately 26%. The selloff intensified in mid-July after the company filed a registration statement covering up to 13.32 million shares for resale by selling stockholders, adding to an already pressured tape. Zooming out to the quarterly perspective, the stock has fallen approximately 36% from around $1.08 in late April, extending a prolonged downtrend driven by persistent capital raises, a low cash runway, and a market capitalization that has shrunk below $40 million. The stock's 52-week range now spans from $0.5068 to $1.55, underscoring the sustained volatility in this small-cap biotech name.
What Drove PDSB Stock Price in the Last 30 Days
The dominant force behind the 30-day decline was dilution risk. On July 10, 2026, PDS Biotech filed a prospectus with the SEC to register the resale of up to 13.32 million shares by a selling stockholder — comprised of approximately 2.16 million shares issuable upon warrant exercise and up to 11.16 million shares upon conversion of a $6 million convertible promissory note that closed on June 15, 2026. The note carries a 10% annual interest rate and was issued at a 4% original issue discount. Combined with a previously disclosed $50 million at-the-market equity offering facility, the potential share overhang has materially pressured the stock.
Additionally, after briefly regaining Nasdaq compliance on June 2, 2026, the stock has once again fallen below the $1.00 minimum bid price requirement, leaving investors to question whether a reverse stock split or another capital raise may be necessary to meet the August 24, 2026 compliance deadline. The company's cash position of $21.7 million as of March 31, 2026, and a quarterly net loss of approximately $7.3 million continue to raise near-term funding concerns. KPMG's going-concern opinion, included in the 2025 10-K filed in March 2026, remains a notable risk factor weighing on sentiment.
What Drove PDSB Stock Performance Over the Last Quarter
Over the broader quarter, PDSB's decline reflects a convergence of financial headwinds that have overshadowed what has otherwise been a period of meaningful clinical progress. The company amended its VERSATILE-003 Phase 3 protocol to add progression-free survival as an interim primary endpoint, creating a potential accelerated approval pathway for PDS0101 while reducing the target patient enrollment by approximately 28%. Positive clinical data published in JCO Oncology Advances showed a 77.8% objective response rate for PDS01ADC in metastatic colorectal cancer, along with an approximately 85% 24-month survival rate — roughly double the rate observed in the parallel control arm. The company also secured new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Despite these advances, the market has remained singularly focused on PDSB's capital structure, with the $6 million convertible note, the ATM facility, and the Nasdaq compliance clock serving as the quarter's headline drivers.
Trending AI Robots
In volatile market environments like the one affecting PDS Biotechnology, traders increasingly turn to data-driven tools to identify opportunities and manage risk. Tickeron's Trending AI Robots page features a curated selection of top-performing AI-powered trading bots drawn from a universe of hundreds of bots trading across thousands of tickers. These bots employ diverse strategies — ranging from momentum-based swing trading to longer-term trend-following approaches — and are evaluated on real-time performance metrics including win rates, drawdown control, and consistency. Only the most relevant and highest-performing bots rise to the Trending section, giving traders an efficient way to discover algorithm-driven strategies tailored to current market conditions. Whether markets are range-bound or trending sharply, the page offers a practical starting point for exploring AI-assisted trading.
PDSB Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for PDSB is the Nasdaq compliance deadline of August 24, 2026. If the stock cannot sustain a closing bid above $1.00 for 10 consecutive business days by that date, the company may need to pursue a reverse stock split or request an additional 180-day extension. The upcoming annual stockholders meeting on August 10, 2026, could provide clarity on any proposed measures. Q2 2026 earnings, expected around mid-August, will shed light on the company's updated cash balance and burn rate as of June 30, 2026. On the clinical front, management has guided that additional data from the fully enrolled colorectal cancer cohort of the PDS01ADC Phase 2 trial is anticipated by year-end. Progress on restarting enrollment in the amended VERSATILE-003 Phase 3 trial and any partnership or licensing announcements will also be critical for sentiment. With a consensus analyst price target of $7.50 — implying significant upside from current levels — the stock's trajectory hinges on the company's ability to navigate its near-term capital constraints while advancing a pipeline that has generated encouraging early efficacy signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PDSB in -3.33% downward trend, declining for three consecutive days on July 29, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PDSB declined for three days, in of 334 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for PDSB entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PDSB's RSI Oscillator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where PDSB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PDSB just turned positive on July 27, 2026. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
PDSB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.852) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PDSB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology